HERVOLUTION Therapeutics Appoints Biotech Builder J. Robert Coleman as CEO to Accelerate Groundbreaking Immunotherapies to Treat Dark Genome Targets in Cancer, Aging, and Neurodegeneration

PDF version here Copenhagen, Denmark & New York, USA — 19 Dec 2023— HERVOLUTION Therapeutics ApS (‘HERVOLUTION’), a pioneering biotechnology company focused on developing novel immunotherapies to treat dark genome targets in cancer, aging, and neurodegeneration, today announces the appointment of J. Robert Coleman, PhD, MBA as its Chief Executive Officer. Robert Coleman PhD, MBA, […]

HERVOLUTION Therapeutics appoints Moderna Co-Founder and MIT Professor Robert S. Langer as Chair of its Scientific Advisory Board

PDF version here • Prof Langer is a world-renowned scientist and entrepreneur who was a driving force behind Moderna’s mRNA nanoparticle Covid vaccine • Prof Langer has joined HERVOLUTION to develop HERVs that are a novel untapped target in oncology and senescence related diseases • Prof Langer’s scientific knowledge and entrepreneurial expertise will help expedite HERVOLUTION’s lead candidate […]

Hervolution announces EUR 6M Seed financing with the participation of the European Innovation Council Fund to develop first-in-class cancer immunotherapy

Download PDF version here • Danish start-up developing immunotherapies designed to fight the tumors from within • Financing supports GMP and tox studies and will advance Hervolution’s first-in-class cancer immunotherapy into First-in-Human clinical trials • Strengthens team with appointment of industry heavyweights Dr. Sven Rohman as Chairman and Dr. Hamina Patel as CMO Copenhagen, Denmark, 24 May 2023: Hervolution, an early-stage biotechnologycompany developing effective immunotherapies targeting the Human Endogenous Retroviruses (HERVs), today announces that it has raised EUR 6M of Seed funding from private investors with the participation of the European Innovation Council (EIC) Fund. The financing will […]

Dr. Martin Gleave joins Hervolution as scientific advisor

Hervolution is pleased to announce a new, exciting collaboration with Dr. Martin Gleave who joins the company as a scientific advisor. Dr. Gleave is a urologic surgeon and Distinguished Professor and Chair of the Department of Urologic Sciences at University of British Columbia, Canada. He is also co-founder and Executive Director of the highly respected […]

Postdoctoral grant allows Hervolution to engage in new exciting collaborations

Following the recruitment of Emeline Ragonnaud, who joined the team from NIH in June this year, Hervolution is now delighted to announce the award of a postdoctoral grant from Innovation Fund Denmark for her project.  The grant has a 3-year perspective and allows Hervolution to establish strategic collaborations with key people within each of their […]

CEO at SIRION, Christian Thirion, joins Hervolution as a Board Member

Hervolution is pleased to welcome Christian O. Thirion, Ph.D., who has joined the Board of Directors in February 2020. Christian is the founder and CEO of SIRION Biotech GmbH, a company that Hervolution recently entered into a partnership with. At SIRION, he has held multiple leadership positions and has been responsible for the scientific direction […]

Former F-star CEO joins Hervolution as strategic advisor

Hervolution can proudly welcome John Haurum, M.D., Ph.D. as a strategic advisor. John Haurum is a Non-executive Director in various European biotech companies, i.e. Synklino, Neophore, and Synact. From 2012 – 2018, Haurum was the CEO of F-star in Cambridge, UK, where he built a successful biotech company that initiated two clinical trials in oncology […]